放射性医薬品市場規模、シェア、成長分析、タイプ別、適応症別、システム別、用途別、エンドユーザー別、地域別- 産業別予測2024-2031

放射性医薬品の世界市場規模は、2022年に65億2,000万米ドルと評価され、2023年の67億4,000万米ドルから2031年には88億1,000万米ドルに成長し、予測期間（2024-2031年）のCAGRは3.4％で成長する見通しです。

PET（陽電子放射断層撮影）やSPECT（単一光子放射コンピュータ断層撮影）のような画像診断技術の進歩により、ヘルスケアの状況は一変しました。これらの技術革新により、慢性疾患の診断における特異度と感度が大幅に向上し、より早く正確な診断が可能になりました。注目すべき例として、GEヘルスケアは2023年6月に、がん免疫療法に対する反応を検出・予測するために設計された初の治験用PET核医学イメージング製品を発売しました。がん、アルツハイマー病、心臓病などの慢性疾患の有病率が上昇していることは、こうした高度な診断ツールの必要性が高まっていることを裏付けています。米国がん協会の予測によると、2024年までに米国では約29万9000人の前立腺がん患者が新たに発生し、男性の8人に1人が毎年診断されることになります。さらに、アルツハイマー病協会のデータによると、現在65歳以上のアメリカ人の約690万人がアルツハイマー病を患っており、この数字は2060年までに1,380万人にまで拡大すると予想されています。このような慢性疾患の急増は、診断と治療における画像診断技術の重要な役割を浮き彫りにするだけでなく、ヘルスケア分野の利害関係者にとっては大きな市場成長機会です。精密な診断ソリューションへの需要が高まり続ける中、革新的なイメージング技術への投資は、進化するヘルスケア市場において大きなリターンをもたらす可能性が高いです。

目次

イントロダクション

• 調査の目的
• 定義
• 市場範囲

調査手法

• 情報調達
• 二次データソースと一次データソース
• 市場規模予測
• 市場の想定と制限

エグゼクティブサマリー

• 市場概要見通し
• 供給需要動向分析
• セグメント別機会分析

市場力学と見通し

• 市場力学
  • 促進要因
  • 機会
  • 抑制要因
  • 課題
• ポーターの分析

主な市場の考察

• 主な成功要因
• 競合の程度
• 主な投資機会
• 市場のエコシステム
• 特許分析
• 規制情勢
• 技術的情勢
• PESTEL分析
• バリューチェーン分析
• サプライチェーン分析

放射性医薬品市場：タイプ別

• 市場概要
• フッ素-18誘導体
  • フッ素-18フルデオキシグルコース（FDG）
  • フッ素-18フッ化ナトリウム
  • フッ素-18フルシコビン
  • フッ素-18フロルベタピル
  • フッ素-18フロルベタベン
  • その他
• テクネチウム99
• ルテチウム（Lu）177
• ガリウム68
  • DOTATATE
  • DOTATOC
• ジルコニウム89
  • 11C-コリン
  • 14C-尿素
• その他

放射性医薬品市場：適応症別

• 市場概要
• 診断
  • 神経学
  • 神経変性疾患（AD、PD、その他）
  • てんかん
• 心臓病学
• その他

放射性医薬品市場：システム別

• 市場概要
• PET
  • スタンドアロンPETシステム
  • ハイブリッドPET/CT
  • ハイブリッドPET/MRI
• SPECT

放射性医薬品市場：用途別

• 市場概要
• 腫瘍学
• 心臓病学
• 消化器内科
• 神経内分泌学
• 神経学
• 腎臓学
• その他

放射性医薬品市場：エンドユーザー別

• 市場概要
• 病院
• 診断ラボ
• その他

放射性医薬品市場：地域別

• 市場概要
• 北米
  • 米国
  • カナダ
• 欧州
  • ドイツ
  • スペイン
  • フランス
  • 英国
  • イタリア
  • その他欧州地域
• アジア太平洋地域
  • 中国
  • インド
  • 日本
  • 韓国
  • その他アジア太平洋地域
• ラテンアメリカ
  • ブラジル
  • その他ラテンアメリカ地域
• 中東・アフリカ（MEA）
  • GCC諸国
  • 南アフリカ
  • その他中東・アフリカ地域

競合情勢

• 上位5社の比較
• 主要企業の市場ポジショニング（2023年）
• 主な市場企業が採用した戦略
• 市場における最近の活動
• 主要企業の市場シェア（2023年）

主要企業プロファイル

• Cardinal Health（US）
• Novartis Company（Switzerland）
• Lantheus（US）
• Curium（France）
• GE HealthCare（US）
• Jubilant Pharma Company（India）
• China Isotope & Radiation Corporation（China）
• Siemens Healthcare GmbH（Germany）
• Bracco（Italy）
• NTP（South Africa）
• Eckert & Ziegler（Germany）
• SHINE Technologies, LLC（US）
• EczacIbasI-Monrol（Turkey）
• IBA Worldwide（Belgium）
• Global Medical Solutions（US）
• BWX Technologies, Inc.（US）
• Institute of Isotopes（Hungary）
• Coqui Radiopharmaceuticals Corp.（US）
• Evergreen Theragnostics, Inc.（US）
• Isotope JSC（Russia）
• PharmaLogic Holdings Corp.（US）

Global Radiopharmaceuticals Market size was valued at USD 6.52 billion in 2022 and is poised to grow from USD 6.74 billion in 2023 to USD 8.81 billion by 2031, growing at a CAGR of 3.4% in the forecast period (2024-2031).

The healthcare landscape has been transformed by advances in imaging techniques like PET (Positron Emission Tomography) and SPECT (Single Photon Emission Computed Tomography), which leverage radiopharmaceuticals to enhance the diagnostic capabilities of traditional imaging modalities, including CT and MRI. These innovations have significantly improved specificity and sensitivity in diagnosing chronic diseases, facilitating earlier and more accurate characterizations. A notable example is GE Healthcare's launch in June 2023 of the first investigational PET nuclear imaging product designed to detect and predict responses to cancer immunotherapies. The rising prevalence of chronic conditions such as cancer, Alzheimer's disease, and heart disease underscores the growing need for these advanced diagnostic tools. Projections from the American Cancer Society indicate that by 2024, there will be approximately 299,000 new prostate cancer cases in the U.S., with 1 in 8 men diagnosed annually. Moreover, data from the Alzheimer's Association reveals that approximately 6.9 million Americans aged 65 and older currently suffer from Alzheimer's disease, a figure expected to escalate to 13.8 million by 2060. This surge in chronic conditions not only highlights the critical role of enhanced imaging techniques in diagnosis and treatment but also signals significant market growth opportunities for stakeholders within the healthcare sector. As demand for precise diagnostic solutions continues to rise, investing in innovative imaging technologies is likely to yield substantial returns in the evolving healthcare market.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Radiopharmaceuticals market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Radiopharmaceuticals Market Segmental Analysis

Global Radiopharmaceuticals Market is segmented on the type, indication, system, application, end user, and region. By component, market is segmented into fluorine-18 derivatives, technetium-99, lutetium (Lu) 177, gallium-68, zirconium-89, and others. By indication, market is segmented into diagnosis, cardiology, and others. By system, market is segmented into PET, and SPECT. By Application, the market is segmented into Oncology, Cardiology, Gastroenterology, Neuroendocrinology, Neurology, Nephrology, Others. By end user, market is segmented into Hospitals, Diagnostic Labs, and Others. By region, the market is segmented into North America, Europe, Asia Pacific, Middle East and Africa, and Latin America.

Driver of the Global Radiopharmaceuticals Market

The escalating incidence of cancer globally is a significant market driver for the Global Radiopharmaceuticals market, as these specialized compounds play a crucial role in targeted and diagnostic oncology. With their ability to provide precise tumor localization and deliver therapeutic agents directly to malignant tissues, radiopharmaceuticals enhance treatment efficacy while minimizing adverse effects. This targeted approach not only improves patient outcomes but also aligns with the rising demand for personalized medicine, further fueling market growth. As healthcare systems increasingly prioritize advanced cancer therapies, the reliance on radiopharmaceuticals is expected to surge, propelling sustained investment and innovation in this sector.

Restraints in the Global Radiopharmaceuticals Market

The stringent regulatory framework governing the manufacture and approval of radiopharmaceuticals serves as a significant market restraint, hindering the growth potential of the sector. Compliance with rigorous safety and quality standards necessitates substantial investments in research, development, and manufacturing processes, often resulting in delayed product launches. The lengthy approval processes imposed by regulatory bodies further exacerbate these challenges, restricting market access for new therapeutic agents and imaging compounds. As manufacturers navigate the complexities of regulatory requirements, the resulting operational hurdles can deter investment and innovation, placing limitations on the overall expansion of the global radiopharmaceuticals market.

Market Trends of the Global Radiopharmaceuticals Market

The Global Radiopharmaceuticals market is witnessing a robust trend towards personalized medicine, driven by the increasing demand for targeted therapies that cater to individual patient profiles. This shift is particularly prominent in oncology and cardiology, where the ability to customize treatments based on specific genetic and disease characteristics enhances the efficacy of radiopharmaceuticals. As healthcare providers emphasize precision medicine, investments in research and development for innovative radiopharmaceuticals are on the rise. Consequently, this trend not only improves patient outcomes but also propels market growth, as stakeholders seek to harness the full potential of targeted therapies in clinical practice.

Table of Contents

Introduction

• Objectives of the Study
• Definitions
• Market Scope

Research Methodology

• Information Procurement
• Secondary & Primary Data Sources
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Market Overview Outlook
• Supply Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Dynamics
  • Drivers
  • Opportunities
  • Restraints
  • Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of Substitute Products
  • Bargaining Power of Buyers
  • Threat of New Entrants
  • Bargaining Power of Suppliers

Key Market Insights

• Key Success Factor
• Degree of Competition
• Top Investment Pockets
• Ecosystem of the Market
• Patent Analysis
• Regulatory Landscape
• Technological Landscape
• PESTEL Analysis
• Value Chain Analysis
• Supply Chain Analysis

Radiopharmaceuticals Market, By Type

• Market Overview
• Fluorine-18 Derivatives
  • Fluorine-18 Fludeoxyglucose (FDG)
  • Fluorine-18 Sodium Fluoride
  • Fluorine-18 Flucicovine
  • Fluorine-18 Florbetapir
  • Fluorine-18 Florbetaben
  • Others
• Technetium-99
• Lutetium (Lu) 177
• Gallium-68
  • Dotatate
  • Dotatoc
• Zirconium 89
  • 11C-choline
  • 14C-urea
• Others

Radiopharmaceuticals Market, By Indication

• Market Overview
• Diagnosis
  • Neurology
  • Neurodegenerative Disease (AD, PD, and Others)
  • Epilepsy
• Cardiology
• Others

Radiopharmaceuticals Market, By System

• Market Overview
• PET
  • Standalone PET systems
  • Hybrid PET/CT
  • Hybrid PET/MRI
• SPECT

Radiopharmaceuticals Market, By Application

• Market Overview
• Oncology
• Cardiology
• Gastroenterology
• Neuroendocrinology
• Neurology
• Nephrology
• Others

Radiopharmaceuticals Market, By End User

• Market Overview
• Hospitals
• Diagnostic Labs
• Others

Radiopharmaceuticals Market Size by Region

• Market Overview
• North America
  • USA
  • Canada
• Europe
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America
  • Brazil
  • Rest of Latin America
• Middle East & Africa (MEA)
  • GCC Countries
  • South Africa
  • Rest of MEA

Competitive Landscape

• Top 5 Player Comparison
• Market Positioning of Key Players, 2023
• Strategies Adopted by Key Market Players
• Recent Activities in the Market
• Key Companies Market Share (%), 2023

Key Company Profiles

• Cardinal Health (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis Company (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Lantheus (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Curium (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GE HealthCare (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Jubilant Pharma Company (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• China Isotope & Radiation Corporation (China)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Siemens Healthcare GmbH (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bracco (Italy)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• NTP (South Africa)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eckert & Ziegler (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• SHINE Technologies, LLC (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• EczacIbasI-Monrol (Turkey)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• IBA Worldwide (Belgium)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Global Medical Solutions (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• BWX Technologies, Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Institute of Isotopes (Hungary)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Coqui Radiopharmaceuticals Corp. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Evergreen Theragnostics, Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Isotope JSC (Russia)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• PharmaLogic Holdings Corp. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments